Evidence map›Paper›PMID 41148233›Full record

ArticleJCI insight2025

Viral reservoir characteristics in lymphoid tissues of HIV-1 elite controllers.

Samantha K Marzi, Chloé M Naasz, Leah Carrere, Carmen Gasca Capote, Isabelle C Roseto, Ce Gao, Matthias Cavassini, Andrea Mastrangelo, Mathias Lichterfeld, Matthieu Perreau and 1 more

Abstract read
In one paragraph

Article in JCI insight, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. The elite controller phenotype.Current opinion in HIV and AIDS · 2026
    Review
  3. The HIV reservoir landscape in elite controllers.Current opinion in HIV and AIDS · 2026
    Review
  4. HIV controllers, lessons learnt from the lymphoid tissues.Current opinion in HIV and AIDS · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Samantha K MarziRagon Institute of MGB, MIT and Harvard and Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Chloé M NaaszRagon Institute of MGB, MIT and Harvard and Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Leah CarrereRagon Institute of MGB, MIT and Harvard and Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Carmen Gasca CapoteInstituto de Biomedicina de Sevilla and Spanish National Research Council, Seville, Spain.
Isabelle C RosetoRagon Institute of MGB, MIT and Harvard and Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Ce GaoRagon Institute of MGB, MIT and Harvard and Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Matthias CavassiniDivision of Infectious Diseases and.
Andrea MastrangeloDivision of Immunology and Allergy, Universite de Lausanne and Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Mathias LichterfeldRagon Institute of MGB, MIT and Harvard and Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Matthieu PerreauDivision of Immunology and Allergy, Universite de Lausanne and Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Xu G YuRagon Institute of MGB, MIT and Harvard and Infectious Disease Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Funding

Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
Delaney AIDS Research Enterprise to Cure HIVUM1AI164560 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS, Sharon Ruth Lewin · 2021 to 2026
$32.0M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Elite controllers as a model for a cure of HIV-1 infectionR37AI155171 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Xu Yu · 2020 to 2026
$5.2M
Single-cell Proteogenomic profiling of HIV-1 reservoir cellsR01AI176579 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Mathias Lichterfeld · 2023 to 2026
$4.6M
Immunoregulatory Function of Myelomonocytic Receptors in HIV-1 InfectionR01AI078799 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2008 to 2017
$4.1M
Selection and Evolution of HIV-1 reservoir cells in blood and tissuesR01AI152979 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ESTES, JACOB D, LICHTERFELD, MATHIAS · 2020 to 2025
$3.8M
Molecular profile of proviral reservoirs in HIV-infected drug usersR61DA047034 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS, YU, XU · 2018 to 2020
$3.4M
A systems biology approach to fingerprint HIV immune defense in Elite ControllersR01HL134539 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI YU, XU · 2016 to 2019
$3.3M
Proteomics and phosphoproteomics analysis in HIV-1 infectionR01AI130005 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LICHTERFELD, MATHIAS · 2017 to 2021
$2.9M
Molecular profile of proviral reservoirs in HIV-infected drug usersR33DA047034 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LICHTERFELD, MATHIAS, YU, XU · 2022 to 2024
$2.0M
Gates Foundation INV-002703NHLBI NIH HHS R01 HL134539NIAID NIH HHS K24 AI155233NIAID NIH HHS R01 AI078799NIAID NIH HHS R01 AI130005NIAID NIH HHS R01 AI152979NIAID NIH HHS R01 AI176579NIAID NIH HHS R21 AI116228NIAID NIH HHS R33 AI116228NIAID NIH HHS R37 AI155171NIAID NIH HHS UM1 AI164560NIAID NIH HHS UM1 AI164562NIAID NIH HHS UM1 AI164566NIAID NIH HHS UM1 AI164570NIDA NIH HHS R33 DA047034NIDA NIH HHS R61 DA047034
6 · The paper itself

Abstract

Elite controllers (ECs) maintain undetectable levels of plasma viremia in the absence of treatment, but small reservoirs of replication-competent proviruses persist in the vast majority of these persons. We longitudinally studied paired blood and inguinal lymph node samples (LNMC) from 2 ECs to better characterize distinguishing features of viral reservoir cell dynamics in ECs. In both participants, we observed a 7- to 10-fold lower frequency of intact proviruses in LNMC samples relative to reservoir cells circulating in blood. The landscape of intact proviruses in both tissue compartments was dominated by shared large clones that were frequently integrated in noncoding DNA regions, but the frequency and diversity of intact proviruses was more limited in LNMCs. Of note, over 9-10 years of longitudinal follow-up, a 3- to 18-fold reduction of intact proviruses was observed. Together, these data support the hypothesis that viral reservoirs in EC blood and lymphoid tissues are under strong, likely immune-mediated selection pressure.

Indexed as

HIV-1HIV InfectionsHIV Long-Term SurvivorsLymph NodesLymphoid TissueProvirusesAdultDisease ReservoirsDNA, ViralFemaleHumansLongitudinal StudiesMaleMiddle AgedViral LoadViremiaDNA, ViralAIDS/HIVInfectious diseaseMolecular biologyVirology

Identifiers

PMID41148233
PMCPMC12890494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.